• PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK

    Oct 1, 2018, 00:00

  • PSY92 - ECONOMIC AND PATIENT OUTCOMES OF GENERIC AND BRAND-NAME STATINS USED IN ROUTINE CLINICAL PRACTICE IN SPAIN

    Oct 1, 2018, 00:00

  • PSS63 - IDENTIFYING PATIENT PREFERENCES FOR GLAUCOMA TREATMENT- EVIDENCE FROM LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN32 - THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PHP88 - CLINICAL ADDED VALUE ASSESSMENT OF ANTI-INFECTIVES FOR SYSTEMIC USE BY FRENCH TRANSPARENCY COMMITTEE IS CORRELATED WITH THE PUBLIC HEALTH BENEFIT

    Oct 1, 2018, 00:00

  • PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS- A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.

    Oct 1, 2018, 00:00

  • PHP42 - EARLY ACCESS PROGRAMS- A COMPARISON BETWEEN FRANCE, GERMANY AND THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PSS8 - IDENTIFYING THE CONFOUNDERS THAT EXPLAIN THE DIFFERENCE IN READOUTS BETWEEN NON-INTERVENTIONAL STUDIES (NIS) AND RANDOMIZED CONTROLLED TRIALS (RCTS)- THE CASE OF TREATMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)

    Oct 1, 2018, 00:00

  • PMH5 - HELP-SEEKING BEHAVIOR AND RISK OF SUICIDE ATTEMPT IN HEAVY DRINKERS- RESULTS FROM A NATIONAL 3-YEAR LONGITUDINAL STUDY

    Oct 1, 2018, 00:00

  • PCV89 - CLINICAL AND ECONOMIC BURDEN OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILURE

    Oct 1, 2018, 00:00

  • PSY124 - COST OF ALLOGENEIC HSCT COMPLICATIONS IN BRAZIL- A DETERMINISTIC LINKAGE APPROACH FOCUSING ON PATIENTS WITH GVHD

    Oct 1, 2018, 00:00

  • PRM206 - THE PERIODIC SYSTEMATIC REVIEW FOR BIBLIOPRO- A DECADE OF SPANISH PATIENT-REPORTED OUTCOMES.

    Oct 1, 2018, 00:00

  • PMD70 - ECONOMIC EVALUATION OF THE BURDEN OF PREECLAMPSIA WITHIN AN ITALIAN REGIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PMU85 - CONSUMER SURVEY OF HEALTH AND RECREATIONAL TOURISM IN THE WEST-TRANSDANUBIAN REGION OF HUNGARY

    Oct 1, 2018, 00:00

  • PSY83 - IMPACT OF DOSE ESCALATION ON AVERAGE COST AND COST-EFFECTIVENESS OF ANTI-TNF AND USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SWEDEN

    Oct 1, 2018, 00:00

  • PHP285 - EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKING

    Oct 1, 2018, 00:00

  • PRM244 - USING A PARAMETRIC APPROACH TO SIMULATE THE FREQUENCY OF MIGRAINE HEADACHE DAYS IN PATIENTS WITH CHRONIC MIGRAINE WITH DATA FROM THE REGAIN STUDY

    Oct 1, 2018, 00:00

  • PHP301 - THE TIME IS NOW FOR EUROPEAN HTA- HOW WILL THE EVOLUTION OF EUROPEAN HTA IMPACT ACCESS TO INNOVATIVE MEDICINES?

    Oct 1, 2018, 00:00

  • PCN288 - HAS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY DRUGS DELIVERED FASTER PATIENT ACCESS TO INNOVATIVE TREATMENTS?

    Oct 1, 2018, 00:00

  • PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACK

    Oct 1, 2018, 00:00

  • PND42 - BURDEN OF MULTIPLE SCLEROSIS IN RUSSIA AND EUROPE

    Oct 1, 2018, 00:00

  • PMH48 - PHARMACOECONOMIC STUDY OF THE EFFECTIVENESS AND SAFETY OF ANTIPSYCHOTICS

    Oct 1, 2018, 00:00

  • PMU57 - COST-EFFECTIVENESS OF VACCINATION STRATEGIES TO PREVENT INFECTIOUS DISEASES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM124 - MODELLING LIKELY CARDIOVASCULAR DISEASE MORTALITY WITH PCSK9 INHIBITORS USING A SYNTHETIC POPULATION

    Oct 1, 2018, 00:00

  • PIN22 - A PAYER PERSPECTIVE OF THE HOSPITAL INPATIENT ADDITIONAL CARE COSTS OF ANTIMICROBIAL RESISTANCE IN FRANCE- A MATCHED CASE-CONTROL STUDY

    Oct 1, 2018, 00:00

  • PRM104 - EVALUATION OF DATA COLLECTION DURATION IN RETROSPECTIVE NONINTERVENTIONAL MEDICAL RECORD REVIEW ONCOLOGY STUDIES CONDUCTED IN THE UNITED STATES (US), CANADA, UNITED KINGDOM (UK), GERMANY, FRANCE AND SPAIN

    Oct 1, 2018, 00:00

  • PIH14 - FACTORS ASSOCIATED WITH THE USE OF ANTIPYRETICS IN CHILDREN OF PARENTS IN A COHORT SAMPLE IN SAUDI ARABIA

    Oct 1, 2018, 00:00

  • DB3 - PROOF-OF-CONCEPT STUDY OF DIGITAL SMARTPHONE APPLICATIONS TO SUPPORT SELF-MANAGEMENT OF LONG-TERM HEALTH CONDITIONS

    Oct 1, 2018, 00:00

  • PRM223 - THE MISSING DATA PROBLEM- USING PROPENSITY SCORES TO ESTIMATE NON-RANDOMISED TREATMENT EFFECTS WITH MISSING COVARIATE DATA

    Oct 1, 2018, 00:00

  • PND81 - HEALTH SERVICE USE IN HIGH AND LOW SEVERITY DRAVET SYNDROME IN THE EU5

    Oct 1, 2018, 00:00

  • CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS- HOW IGNORING THE MODEL’S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)

    Oct 1, 2018, 00:00

  • PND65 - COST-EFFECTIVENESS ANALYSIS OF DRUGS USED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PSY147 - AVAILABILITY AND REIMBURSEMENT OF ORPHAN DRUGS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PRM107 - CAN ACCOUNTING FOR MISSING DATA CAST DOUBT ON PREVIOUS CONCLUSIONS REEVALUATING A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)?

    Oct 1, 2018, 00:00

  • PHP290 - IMPLICATIONS OF CONDITIONAL APPROVAL AND APPROVAL UNDER EXCEPTIONAL CIRCUMSTANCES BY THE EUROPEAN MEDICINES AGENCY ON NICE APPRAISALS

    Oct 1, 2018, 00:00

  • PMU92 - CAN THE EQ-5D-3L PREDICT POST-HOSPITALIZATION HEALTHCARE USE AND OUTCOMES?

    Oct 1, 2018, 00:00

  • PND147 - WALKING DISORDERS IN MS- HOW DO THEY IMPACT PATIENTS’ QUALITY OF LIFE? RESULTS FROM AN OBSERVATIONAL STUDY CONDUCTED VIA AN ONLINE PATIENT COMMUNITY

    Oct 1, 2018, 00:00

  • PRM243 - NETWORK META-ANALYSES ON SURVIVAL DATA- A COMPARISON AND GUIDANCE FOR DIFFERENT METHODOLOGIES

    Oct 1, 2018, 00:00

  • PHP192 - HTA EDUCATIONAL NEEDS IN CENTRAL-EASTERN-SOUTH EUROPEAN (CESE) COUNTIRES – RESULTS OF JOC HTA PROJECT

    Oct 1, 2018, 00:00

  • PCV83 - KEY MODEL PARAMETERS AND METHODOLOGIES USED IN COST-EFFECTIVENESS ANALYSIS EVALUATING TREATMENTS FOR SECONDARY PREVENTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) OR ACUTE COR ...

    Oct 1, 2018, 00:00

  • PDB117 - CHANGES IN PATIENT REPORTED OUTCOMES, ATTITUDES AND HEALTH BEHAVIORS IN 606 PEOPLE WITH DIABETES FOLLOWING 2 MONTHS USE OF THE DRUGSTARS HEALTH APP

    Oct 1, 2018, 00:00

  • PND80 - AN OBSERVATIONAL STUDY OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS IN FRANCE- FIRST INTERIM ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION FROM THE BRIO STUDY

    Oct 1, 2018, 00:00

  • PIN106 - GETTING CLOSER TO THE GOAL- MEASUREMENT OF THE 90 90 90 TARGETS TO END THE AIDS EPIDEMIC IN THE COLOMBIAN HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • AC3 - DISCORDANT DESIGNATIONS OF BREAKTHROUGH DRUG INNOVATION- FRANCE VERSUS THE UNITED STATES

    Oct 1, 2018, 00:00

  • PSY59 - ORPHAN DRUGS PRICES COMPARISON IN MIDDLE EAST NORTH AFRICA (MENA) REGION

    Oct 1, 2018, 00:00

  • PRM210 - METHODS USED TO IDENTIFY PATIENT REPORTED OUTCOME MEASURES IN VASCULAR DISEASES

    Oct 1, 2018, 00:00

  • PIN102 - IMPACT OF DEPRESSION AND ITS ASSOCIATION TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ADHERENCE AND ADVERSE DRUG REACTIONS IN PEOPLE LIVING WITH HIV IN INDIA

    Oct 1, 2018, 00:00

  • PHP297 - CHANGES IN ULTRA-ORPHAN DRUG ASSESSMENTS IN POLAND

    Oct 1, 2018, 00:00

  • Copyright/Subscription

    Oct 1, 2018, 00:00

  • PIN109 - EVALUATION OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING HIV/AIDS AMONG PREGNANT WOMEN AND THEIR PARTNERS INVOLVED IN PREVENTION MOTHER-TO-CHILD TRANSMISSION (PMTCT) PROGRAMS IN MALAWI.

    Oct 1, 2018, 00:00

  • PGI9 - SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF INFLIXIMAB BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PGI49 - HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE

    Oct 1, 2018, 00:00

  • PCP25 - ARTIFICIAL INTELLIGENCE ASSISTED LITERATURE REVIEWS- KEY CONSIDERATIONS FOR IMPLMENTATION IN HEALTH CARE RESEARCH

    Oct 1, 2018, 00:00

  • PHP207 - ASSESSMENT OF PHARMACIST MEDICATION CONSULTATION IN COMMUNITY PHARMACIES LOCATED IN TEHRAN

    Oct 1, 2018, 00:00

  • PND141 - CHARACTERISTICS AND MANAGEMENT OF MIGRAINE PATIENTS WHO HAVE FAILED PRIOR PREVENTIVE TREATMENT IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCP10 - PATIENT ACCESS TO NEW MEDICINES; THE CHANGING LANDSCAPE

    Oct 1, 2018, 00:00

  • PHP69 - A REVIEW OF FUNDING PATHS FOR E-HEALTH SOLUTIONS IN THE EU5, US AND CANADA

    Oct 1, 2018, 00:00

  • PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIA

    Oct 1, 2018, 00:00

  • PMD108 - COST-EFFECTIVENESS OF LEFT VENTRICULAR ASSIST DEVICES IN END STAGE HEART FAILURE USING STATE TRANSITION MODELLING BASED ON REGISTRY DATA

    Oct 1, 2018, 00:00

  • PMD15 - COMPUTER-ASSISTED (TAONET®) AND MANUAL DOSAGE CONTROL OF PATIENTS ON ORAL ANTICOAGULANT THERAPY IN ROUTINE CLINICAL PRACTICE. PRELIMINARY RESULTS OF A MULTICENTER STUDY

    Oct 1, 2018, 00:00

  • PHP94 - DOES THE ORPHAN DESIGNATION INCREASE THE CHANCES OF POSITIVE HTA OPINION IN FRANCE, GERMANY AND UK?

    Oct 1, 2018, 00:00

  • PRM162 - A PIECEWISE APPROACH TO THE EXTRAPOLATION OF INVASIVE DISEASE-FREE SURVIVAL (IDFS) IN THE ADJUVANT TREATMENT OF HER2+ BREAST CANCER

    Oct 1, 2018, 00:00

  • PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCER

    Oct 1, 2018, 00:00

  • PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCP35 - A MODERN MEDICAL KNOWLEDGE IN MANAGEMENT OF PATIENTS WITH INFLUENZA IN UKRAINE

    Oct 1, 2018, 00:00

  • PHP299 - THREE YEARS OF SINATS

    Oct 1, 2018, 00:00

  • PCN302 - IS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY INDICATIONS TOO POSITIVE IN ITS ASSESSMENT OF CANCER DRUGS IN ENGLAND?

    Oct 1, 2018, 00:00

  • PMD162 - AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) NEWBORN SCREENING (NBS) RECOMMENDATIONS- SENSITIVITY TO ACCOUNTING FOR REPORTED MISSING DATA IN THE CASE OF GLUTARIC ACIDURIA II (GAII)

    Oct 1, 2018, 00:00

  • PCN334 - OUTCOMES OF PERIPHERAL T-CELL LYMPHOMA (PTCL) PATIENTS TREATED IN THE REAL WORLD

    Oct 1, 2018, 00:00

  • PMS105 - EXAMINATION OF CORE TRAINING PROGRAM ON THE CHANGE OF LOW BACK PAIN, MUSCLE STRENGTH AND LUMBAR MOTOR CONTROLL AMONG PROFESSIONAL FIREFIGHTERS

    Oct 1, 2018, 00:00

  • PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS- A SURVIVAL MODEL ANALYSIS

    Oct 1, 2018, 00:00

  • PMS26 - COMPARATIVE TREATMENT COSTS OF SURGICAL VS NON-SURGICAL PATIENTS WITH MEDIAL MENISCUS DEFICIENCY- RESULTS FROM A 24-MONTH SURVEILLANCE STUDY

    Oct 1, 2018, 00:00

  • PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALY

    Oct 1, 2018, 00:00

  • PRM83 - COMPARATIVE ASSSESMENT OF ORAL ANTIDIABETIC DRUG-MEDIATED GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS BETWEEN TWO DIFFERENT REAL-WORLD DATABASES

    Oct 1, 2018, 00:00

  • PRS69 - IMPACT OF THE INTERNATIONAL REFERENCE PRICING ON ACCESS TO STANDARD THERAPY DRUGS FOR COPD

    Oct 1, 2018, 00:00

  • PCV106 - EVALUATION OF PRICES AND SALES VOLUME OF CARDIO-VASCULAR MEDICINES IN COMMUNITY PHARMACIES

    Oct 1, 2018, 00:00

  • PMU23 - ANALYSIS OF PATIENT SAFETY INCIDENTS REPORTS AT A UNIVERSITARY HOSPITAL

    Oct 1, 2018, 00:00

  • PRM14 - USING EXPERT ELICITATION TO CAPTURE COST-EFFECTIVENESS MODEL UNCERTAINTIES- VALUING EXPERTS' CONTRIBUTION

    Oct 1, 2018, 00:00

  • PSS23 - SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS

    Oct 1, 2018, 00:00

  • PCN305 - NICE AND THE CANCER DRUGS FUND – CAN OBSERVATIONAL EVIDENCE INFORM FUNDING DECISIONS IN ONCOLOGY?

    Oct 1, 2018, 00:00

  • PMS94 - AVAILABILITY OF TOOLS TO ASSESS PROMS IN HIP ARTHROPLASTY IN SPAIN. A SYSTEMATIC REVIEW.

    Oct 1, 2018, 00:00

  • PSY172 - REAL WORLD EVIDENCE OF HEREDITARY HYPOPHOSPHATEMIA IN GERMANY – ANALYSIS OF GERMAN SHI CLAIMS DATA FOR PEDIATRIC PATIENTS

    Oct 1, 2018, 00:00

  • PMS40 - COST – EFFECTIVENESS STUDY OF ETANERCEPT AS FIRST LINE TREATMENT FOR ANKYLOSING SPONDYLITIS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PHP138 - CHANGES IN THE NUMBER OF MIDWIVES IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PSY44 - TOCILIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE TREATMENT OF GIANT CELL ARTERITIS- A BUDGET IMPACT ANALYSIS IN ITALY

    Oct 1, 2018, 00:00

  • PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP87 - COULD THE FRENCH COHORT ATU PROGRAM BE THE MODEL EUROPE NEEDS TO HARMONIZE COMPASSIONATE USE PROGRAMS?

    Oct 1, 2018, 00:00

  • PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIA

    Oct 1, 2018, 00:00

  • PRM18 - REAL-WORLD DATA (RWD) COLLECTION ALONGSIDE EARLY ACCESS TO MEDICINES SCHEMES (EAMS) - NIVOLUMAB IN GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJ) AFTER TWO OR MORE PRIOR THERAPIES

    Oct 1, 2018, 00:00

  • PRS88 - COMPARABILITY OF A PROVISIONED DEVICE VERSUS BRING YOUR OWN DEVICE FOR COMPLETION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES BY PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- QUANTITATIVE STUDY FINDINGS

    Oct 1, 2018, 00:00

  • PCN314 - HEALTH-TECHNOLOGY ASSESSMENTS IN ONCOLOGY- RESULTS OF A REVIEW OF DECISIONS IN GERMANY

    Oct 1, 2018, 00:00

  • PMS45 - COST PER RESPONDER ANALYSIS FOLLOWING A 48-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ADALIMUMAB FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSS7 - QUALITY OF LIFE IMPROVEMENTS IN PSORIASIS WITH SECUKINUMAB IN A DIFFICULT TO TREAT POPULATION OF ANTI-TNF ALPHA FAILURE PATIENTS FROM THE UK AND REPUBLIC OF IRELAND

    Oct 1, 2018, 00:00

  • PMD9 - ANALYSIS OF DYSLIPIDEMIA AMONG PATIENTS WITH DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM275 - FIELD RESEARCH FOR THE DETERMINATION OF THE INDIRECT COSTS OF PERITONEAL DIALYSIS AND HEMODIALYSIS IN TURKEY

    Oct 1, 2018, 00:00

  • PHP349 - THE EVOLUTION OF STANDARD MONITORING REGISTRIES IN THE ITALIAN MARKET

    Oct 1, 2018, 00:00

  • PCN258 - HEALTHCARE RESOURCE UTILISATION (HCRU) AMONG PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN- THE SCAN-LEAF STUDY

    Oct 1, 2018, 00:00

  • PMD74 - HIGH RESOLUTION MELTING FOR THE SCREENING OF RESISTANCE-ASSOCIATED MUTATIONS IN MYCOBACTERIUM LEPRAE IN LEPROSY PATIENTS WITH SUSPECTED RELAPSE ASSOCIATED WITH RESISTANCE.

    Oct 1, 2018, 00:00

  • PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY- A BUDGET IMPACT ANALYSIS

    Oct 1, 2018, 00:00

  • PSS12 - PREVALENCE OF NEUROTROPHIC KERATOPATHY IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PDB47 - THE ASSOCIATION BETWEEN RENAL FUNCTION AND HEALTHCARE COSTS IN US PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PSS3 - A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE STUDIES OF INTRAVITREAL AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION

    Oct 1, 2018, 00:00

  • PND79 - REDUCED HEALTHCARE RESOURCE UTILISATION FOR PATIENTS TREATED WITH DELAYED RELEASE DIMETHYL FUMARATE VS INJECTABLE THERAPIES- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY OF MS PATIENTS

    Oct 1, 2018, 00:00

  • PSY47 - AN ECONOMIC EVALUATION OF IRON ISOMALTOSIDE 1000 VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN DENMARK

    Oct 1, 2018, 00:00

  • PCN141 - COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECE

    Oct 1, 2018, 00:00

  • PRM34 - FRENCH EFFICIENCY OPINIONS OF THE ECONOMIC AND PUBLIC HEALTH COMMITTEE (CEESP)- IS THERE AN IMPACT ON THE MARKET ACCESS FOR INNOVATIVE DRUGS?

    Oct 1, 2018, 00:00

  • PHP101 - SOCIO-ECONOMIC AND SOCIO-DEMOGRAPHIC DRIVERS INFLUENCING PREVALENCE OF ANTIBIOTIC USE- AN ANALYSIS IN SOUTHERN ITALY SETTING

    Oct 1, 2018, 00:00

  • PIN51 - COST-EFFECTIVENESS OF LEDIPASVIR/SOFOBUVIR IN HEPATITIS C TREATMENT- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • RM4 - EXPLORING TIME-DEPENDENT VARIATION OF PATIENT-REPORTED OUTCOME SCORES ACROSS DIFFERENT TIME-POINTS FOR PATIENTS WITH MULTIPLE CONDITIONS- A MIXED METHODS LONGITUDINAL STUDY

    Oct 1, 2018, 00:00

  • PHP129 - CHALLENGES AND OPPORTUNITIES IN THE BIOLOGICALS-BIOSIMILARS MARKET- SUSTAINABILITY AND MARKET DIFFERENTIATION

    Oct 1, 2018, 00:00

  • PSY87 - ECONOMIC BURDEN OF TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY

    Oct 1, 2018, 00:00

  • PCP59 - IDENTIFICATION, SELECTION AND MEASUREMENT OF OUTCOMES TO FACILITATE THE USE OF BIG DATA- A TOOLKIT

    Oct 1, 2018, 00:00

  • PSS20 - ECONOMIC BURDEN OF PSORIASIS (PSO) IN TURKEY

    Oct 1, 2018, 00:00

  • PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PRM122 - BOOTSTRAPPING PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL TO CAPTURE THEIR CORRELATION IN PROBABILISTIC SENSITIVITY ANALYSES

    Oct 1, 2018, 00:00

  • PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMEN

    Oct 1, 2018, 00:00

  • PHP1 - EXPECTED DEMAND FOR HEALTH SERVICES FROM A VOLUNTARY INSURER

    Oct 1, 2018, 00:00

  • PHP280 - IS THERE A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS?

    Oct 1, 2018, 00:00

  • PSY78 - THE ECONOMIC AND HEALTHCARE BURDEN OF ANCA-ASSOCIATED VASCULITIS (AAV) IN GERMANY

    Oct 1, 2018, 00:00

  • PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN’S LYMPHOMA

    Oct 1, 2018, 00:00

  • PGI51 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT HIGHER ECONOMIC BURDEN THAN CONTROLS- RESULTS FROM THE EU5 NATIONAL HEALTH AND WELLNESS SURVEY

    Oct 1, 2018, 00:00

  • PRS35 - THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE IN THE UK HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PRS25 - A RETROSPECTIVE DATABASE STUDY TO DEFINE A PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENT COHORT AND EVALUATE THE ECONOMIC BURDEN OF ILLNESS IN FRANCE

    Oct 1, 2018, 00:00

  • PRM195 - THE INFANT GASTROESOPHAGEAL REFLEX DISEASE QUESTIONNAIRE (I-GERQ-R)- A META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMH54 - PATTERNS OF LONG-TERM CUSTODIAL CARE IN PARKINSON DISEASE PSYCHOSIS

    Oct 1, 2018, 00:00

  • PRS96 - PATIENT PERCEIVED IMPACT OF NURSE-LED SELF-MANAGEMENT INTERVENTIONS FOR COPD- A SYSTEMATIC REVIEW OF QUALITATIVE RESEARCH

    Oct 1, 2018, 00:00

  • PHP340 - UNDERSTANDING PHYSICIANS’ CONCEPTION OF QUALITY OF HEALTH CARE DELIVERY- AN EXPLORATIVE STUDY USING THE REPERTORY GRID TECHNIQUE

    Oct 1, 2018, 00:00

  • PSS46 - DIFFERENCES IN HTA COVERAGE RECOMMENDATIONS- COMPARING OPHTHALMOLOGY DRUG REIMBURSEMENT DECISIONS IN FOUR EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCV16 - A SYSTEMATIC REVIEW ON THE EFFICACY OF PHARMACOLOGICAL TREATMENTS IN PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF)

    Oct 1, 2018, 00:00

  • PIN32 - THE PUBLIC HEALTH AND ECONOMIC IMPACT OF INCREASED SCREENING AND IMMEDIATE INITIATION OF ANTIRETROVIRAL TREATMENT FOR HIV-1 IN THE UK

    Oct 1, 2018, 00:00

  • PCP17 - IMPACT OF THE ICER VALUE ASSESSMENT FRAMEWORK ON DRUG PRICING IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PRS68 - HEALTH RESOURCE UTILIZATION (HRU) AMONG INFANTS DIAGNOSED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN THE NETHERLANDS- A RETROSPECTIVE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PRM134 - USING ADJUSTED INDIRECT COMPARISON IN HTA TO OVERCOME SHORT FOLLOW-UP TIME IN REGULATORY RANDOMIZED CONTROLED CLINICAL TRIALS- RIBOCICLIB AS FIRST-LINE THERAPY FOR HR-POSITIVE, ADVANCED BREAST CANCER

    Oct 1, 2018, 00:00

  • PMD144 - SELECTIVE HEALTH BENEFIT TO REDUCE ECONOMIC BURDEN OF PATIENTS- CASE OF CANCER SURGERY

    Oct 1, 2018, 00:00

  • PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC)- RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

    Oct 1, 2018, 00:00

  • PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PMS2 - RETROSPECTIVE STUDY TO EVALUATE OSTEOARTHRITIS POPULATION IN GERMANY AND IDENTIFY INFLUENTIAL FACTORS IN FAST, MEDIUM AND SLOW PROGRESSING PATIENTS

    Oct 1, 2018, 00:00

  • PSY18 - RAPID IMPROVEMENTS IN MOTOR FUNCTION IN SPINAL MUSCULAR ATROPHY TYPE 1 FOLLOWING AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIA

    Oct 1, 2018, 00:00

  • PMH41 - COST-UTILITY ANALYSES OF INFORMAL CAREGIVER INTERVENTIONS- A CRITICAL REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PCV79 - REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PSY43 - BUDGET IMPACT ANALYSIS OF METHOXYFLURANE (PENTHROX®) FOR EMERGENCY RELIEF OF MODERATE-TO-SEVERE TRAUMA PAIN IN THE SWEDISH SETTING

    Oct 1, 2018, 00:00

  • PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAIN

    Oct 1, 2018, 00:00

  • PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?

    Oct 1, 2018, 00:00

  • PCN307 - APPLYING MULTI-CRITERIA DECISION ANALYSIS (MCDA) AS AN EVIDENCE BASED HEALTH TECHNOLOGY ASSESSMENT IN HEALTH CARE DECISION MAKING IN EGYPT

    Oct 1, 2018, 00:00

  • PDB8 - FACTORS ASSOCIATED WITH UNCONTROLLED GLYCEMIA AMONG OUTPATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTING

    Oct 1, 2018, 00:00

  • PHP34 - TIME ANALYSIS OF THE DRUG APPROVAL PROCESS IN EUROPE

    Oct 1, 2018, 00:00

  • PCN235 - COMBINATION ONCOLOGY THERAPIES IN THE EU5- NAVIGATING THE ROAD TO REIMBURSEMENT AND OPTIMIZING UPTAKE IN MALIGNANT MELANOMA

    Oct 1, 2018, 00:00

  • PSY21 - DELETERIOUS EFFECT OF BLOOD TRANSFUSIONS IN A COHORT OF ANAEMIC INPATIENTS

    Oct 1, 2018, 00:00

  • PHP328 - REAL-WORLD-DATA AND REAL-WORLD-EVIDENCE STATE OF ART FROM A LITERATURE REVIEW PERSPECTIVE

    Oct 1, 2018, 00:00

  • Economic Analysis of Vaccination Programs

    Oct 1, 2018, 00:00

  • PCN311 - EUROPEAN MARKET ACCESS CHALLENGES FOR RELAPSED REFRACTORY MULTIPLE MYELOMA TRIPLET THERAPIES

    Oct 1, 2018, 00:00

  • PCN393 - THE BURDEN OF INFORMAL CARE FOR BREAST CANCER PATIENTS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PSY11 - REAL-WORLD EXPERIENCE OF GENERALIZED LIPODYSTROPHY PATIENTS ENROLLED IN THE METRELEPTIN EARLY ACCESS PROGRAM- INITIAL RESULTS

    Oct 1, 2018, 00:00

  • PND8 - PEGINTERFERON BETA-1A IS ASSOCIATED WITH REDUCED RELAPSE RATES AND HOSPITALISATIONS DUE TO RELAPSE COMPARED WITH OTHER FIRST-LINE INJECTABLE THERAPIES FOR MULTIPLE SCLEROSIS- FINDINGS FROM A REAL-WORLD CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PMS58 - ECONOMIC EVALUATION OF ANTERIOR APPROACH OF TOTAL HIP ARTHROPLASTY IN A TERTIARY HOSPITAL SETTINGS IN HUNGARY- A COST MINIMIZATION STUDY

    Oct 1, 2018, 00:00

  • PHP57 - EUROPEAN CONDITIONAL MARKETING AUTHORIZATION – DOES EARLY MARKETING AUTHORIZATION TRANSLATE INTO EARLY REIMBURSEMENT AND PATIENT ACCESS?

    Oct 1, 2018, 00:00

  • PCP54 - OVERVIEW OF METHODS FOR ASSESSING COMPARATIVE EVIDENCE FOR TREATMENTS EVALUATED IN EARLY PHASE TRIALS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PMD105 - EVALUATING THE COST-EFFECTIVENESS OF SCREENING FOR THE GENETIC RISK OF THROMBOSIS DURING THE RECOMMENDATION OF COMBINED HORMONAL CONTRACEPTION FOR FIRST-TIME USERS IN SWITZERLAND

    Oct 1, 2018, 00:00

  • PRS48 - COST – EFFECTIVENESS ANALYSIS OF VILANTEROL/FLUTICASONE FUROATE FOR ASTHMA TREATMENT IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PSS58 - TREATMENT PATTERNS FOR AGE-RELATED MACULAR DEGENERATION IN SPAIN- KEYS FOR IMPROVING MANAGEMENT IN DAILY CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PCN207 - NEW DRG-BASED REIMBURSEMENT OF ANTINEOPLASTIC PHARMACOTHERAPY AT RUSSIAN HOSPITALS

    Oct 1, 2018, 00:00

  • PCV147 - A TARGETED LITERATURE REVIEW OF HEALTH STATE UTILITIES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

    Oct 1, 2018, 00:00

  • PCV66 - COSTS OF EARLY REHABILITATION AFTER STROKE IN CZECH CEREBROVASCULAR CENTERS

    Oct 1, 2018, 00:00

  • PMD149 - CLAVICLE FRACTURE- TREATMENT, COMPLICATIONS, AND COST IN THE COMMERCIALLY-INSURED POPULATION

    Oct 1, 2018, 00:00

  • PCN162 - DENOSUMAB VERSUS BISPHOSPHONATES FOR THE TREATMENT OF BONE METASTASES FROM SOLID TUMORS- A SYSTEMATIC REVIEW OF ECONOMIC STUDIES

    Oct 1, 2018, 00:00

  • PUK19 - COST-UTILITY OF SUCROFERRIC OXYHYDROXIDE FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN CANADA

    Oct 1, 2018, 00:00

  • PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5

    Oct 1, 2018, 00:00

  • PRM186 - MEASUREMENT PROPERTIES OF TRANSLATED VERSIONS OF MEASURES ASSESSING THE SUBJECTIVE EFFECTS OF TOBACCO- AND NICOTINE-CONTAINING PRODUCTS- A LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY137 - ORPHAN DRUG ACCESS AND REIMBURSEMENT IN THE EU5- CYSTIC FIBROSIS AND DUCHENNE MUSCULAR DYSTROPHY

    Oct 1, 2018, 00:00

  • PUK18 - ECONOMIC EVALUATION OF THE USE OF SEVELAMER (RIFOSAR®) FOR THE TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC RENAL DISEASE, FROM THE PERSPECTIVE OF THE INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)

    Oct 1, 2018, 00:00

  • PMD36 - BUDGET IMPACT ANALYSIS OF THE USE OF LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA IN ITALY

    Oct 1, 2018, 00:00

  • PRM59 - DEVELOPING A MODELLING FRAMEWORK TO ASSESS THE COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS

    Oct 1, 2018, 00:00

  • PHP260 - A EUROPEAN ANALYSIS OF FIXED DOSE COMBINATIONS PRICE SETTING

    Oct 1, 2018, 00:00

  • PCV105 - POTENTIAL REDUCTION IN MORTALITY AND HOSPITALISATIONS WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN IRELAND

    Oct 1, 2018, 00:00

  • PDB133 - CHRONIC KIDNEY DISEASE, HEALTH MEASURES AND HEALTHCARE UTILIZATION AMONG ADULTS WITH DISBETES IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PRM10 - METHODOLOGICAL ASSESSMENT OF ECONOMIC ANALYSES ON COMPUTERIZED PHYSICIAN ORDER ENTRY SYSTEMS AND RELATED CLINICAL DECISION SUPPORT TOOLS IN INPATIENT CARE

    Oct 1, 2018, 00:00

  • PSS11 - PATIENTS UNDER ATOPIC DERMATITIS TREATMENT IN PORTUGAL- RESULTS FROM A PHYSICIANS’ SURVEY

    Oct 1, 2018, 00:00

  • PRM268 - EVALUATION OF REAL-WORLD DATA COLLECTION AND EVIDENCE GENERATION FROM EARLY ACCESS PROGRAM

    Oct 1, 2018, 00:00

  • HT1 - CONSEQUENCES AND VALIDITY OF AN EMPIRICAL ESTIMATION OF THE NICE COST EFFECTIVENESS THRESHOLD

    Oct 1, 2018, 00:00

  • PRM236 - CALIBRATING MATCHING ADJUSTED INDIRECT COMPARISON ESTIMATE TO REAL-WORLD POPULATION

    Oct 1, 2018, 00:00

  • PND46 - ECONOMIC BURDEN OF FRAGILE X SYNDROME IN EUROPE AND THE US- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PSY119 - TREATMENT PATTERN ANALYSIS AND HEALTHCARE RESOURCE CONSUMPTION ON PATIENTS AFFECTED BY PSORIASIS IN APULIA REGION (ITALY).

    Oct 1, 2018, 00:00

  • PSY200 - PATIENT-REPORTED OUTCOMES MEASURES IN CHILDREN WITH SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PDB4 - THE EFFECT OF STATINS USAGE ON DIABETIC EYE COMPLICATIONS

    Oct 1, 2018, 00:00

  • PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMAB

    Oct 1, 2018, 00:00

  • PCN246 - EVOLUTION OF ONCOLYTICS CONSUMPTION IN PORTUGAL OVER TEN YEARS

    Oct 1, 2018, 00:00

  • PHP128 - 3F - FORMULA FOR FUNDING- RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEM

    Oct 1, 2018, 00:00

  • PRM62 - A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS BASED ON DECISION-ANALYTIC MODELING OF CANCER DRUGS

    Oct 1, 2018, 00:00

  • PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE

    Oct 1, 2018, 00:00

  • PRM112 - INCORPORATION OF ANTI-CANCER DRUGS ADVERSE EVENTS IN HEALTH ECONOMIC OPINIONS OF THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Oct 1, 2018, 00:00

  • PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SM ...

    Oct 1, 2018, 00:00

  • PHP293 - ORPHAN DRUGS IN GERMANY - LESSONS LEARNED FROM AMNOG, BEST AND WORST PRACTICES AND STRATEGIC IMPLICATIONS

    Oct 1, 2018, 00:00

  • PND152 - IMPACT OF INOTERSEN ON GENERIC HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PIN46 - COST-EFFECTIVENESS COMPARISON OF BALOXAVIR MARBOXIL AND LANINAMIVIR FOR THE TREATMENT OF INFLUENZA IN JAPAN

    Oct 1, 2018, 00:00

  • PCV157 - ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND ATRIAL FIBRILLATION SYMPTOM BURDEN- RESULTS OF A STUDY ON ATRIAL FIBRILLATION PATIENTS IN GERMANY, SWEDEN AND SWITZERLAND

    Oct 1, 2018, 00:00

  • PSY132 - ECONOMIC CRISIS AND THE EFFECT ON PHARMACOECONOMICS IN A REGIONAL GENERAL HOSPITAL

    Oct 1, 2018, 00:00

  • PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PRS11 - INITIATION OF TRIPLE THERAPY IN NEWLY DIAGNOSED COPD PATIENTS

    Oct 1, 2018, 00:00

  • PMD96 - THE IMPACT OF STRUCTURAL ASSUMPTIONS ON DECISION UNCERTAINTY- A CASE STUDY ON THE PREVENTION OF NEONATAL INFECTIONS IN PRETERM BABIES

    Oct 1, 2018, 00:00

  • PRM101 - THE COST BURDEN OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PHP54 - DIRECTIVE 2004/18/EC- IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPE

    Oct 1, 2018, 00:00

  • PMU102 - A MULTIVARIATE APPROACH THAT ALLOWS COMPREHENSIVE SCORING OF MULTI-FACETED CONCEPTS- FOCUS ON MEDICINE ACCEPTABILITY IN VULNERABLE POPULATIONS

    Oct 1, 2018, 00:00

  • PSS18 - TREATMENT COSTS OF ATOPIC DERMATITIS IN KOREAN ADULTS ACCORDING TO DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PMD171 - HEALTH TECHNOLOGY ASSESSMENT OF COMPANION DIAGNOSTICS ALONGSIDE THERAPEUTC AGENTS IN ONCOLOGY- EXPERIENCE OF THE NICE TECHNOLOGY APPRAISAL PROGRAMME

    Oct 1, 2018, 00:00

  • PCP64 - DEVELOPMENT AND VALIDATION OF COGNITIVE PERFORMANCE-BASED OUTCOME (PERFO) ASSESSMENTS

    Oct 1, 2018, 00:00

  • PCP69 - APPLICATION DECREE OF JARDE LAW- EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PND9 - MIGRAINE BURDEN BEFORE AND AFTER ERENUMAB TREATMENT- A RESPONDER ANALYSIS IN DIFFICULT-TO-TREAT PATIENTS

    Oct 1, 2018, 00:00

  • PCN348 - QUALITY OF LIFE IN END-STAGE CANCER DISEASE

    Oct 1, 2018, 00:00

  • PCN38 - NIVOLUMAB IS PREDICTED TO HAVE IMPROVED CLINICAL OUTCOMES OVER BEST SUPPORTIVE CARE IN A WESTERN POPULATION OF PRE-TREATED GASTRIC CANCER PATIENTS; AN INDIRECT TREATMENT COMPARISON ANALYSIS

    Oct 1, 2018, 00:00

  • PMU14 - COMPARISON TO STANDARD OF CARE- MODELISATION OF POTENTIAL SELECTION BIAS FOR ACTIVE REFERENCE IN RANDOMISED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PCV154 - ASSESSING DIFFERENTIAL ATTRIBUTES OF DIRECT ORAL ANTICOAGULANTS WITH IMPACT ON PATIENT PREFERENCES. A PILOT STUDY

    Oct 1, 2018, 00:00

  • PDB13 - SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 INHIBITORS AND METFORMIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 1 DIABETES

    Oct 1, 2018, 00:00

  • PCV40 - BUDGET IMPACT ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES- A COMPARISON IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PHP185 - BRAZIL'S ECONOMIC SITUATION AND THE EVOLUTION OF THE PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PND114 - IMPACT OF A PHARMACIST-LED COMMUNITY INTERVENTIONAL PROGRAM TO PREVENT COGNITIVE DETERIORATION IN COMMUNITY-DWELLING HONG KONG ELDERS WITH HIGH ANTICHOLINERGIC COGNITIVE BURDEN

    Oct 1, 2018, 00:00

  • PRM228 - EXTRAPOLATION OF SURVIVAL CURVES USING EXTERNAL INFORMATION- IMPLEMENTATION OF GUYOT’S METHOD IN PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE

    Oct 1, 2018, 00:00

  • PDB55 - ECONOMIC ANALYSIS OF TYPE-2 DIABETES MELLITUS IN VIETNAM- A RETROSPECTIVE STUDY AT A DISTRICT HOSPITAL, BA RIA - VUNG TAU PROVINCE

    Oct 1, 2018, 00:00

  • PHP41 - IMPACT OF PRICE REGULATION ORDINANCE ON TOP 20 PRESCRIBED MEDICINES PRICES IN BOSNIA AND HERZEGOVINA

    Oct 1, 2018, 00:00

  • PCN389 - QUALITY OF LIFE USING EQ-5D-3L MEASURE BEFORE ICU ADMISSION TO PREDICT THE MORTALITY OF CRITICALLY ILL CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PMS113 - TOWARD PATIENT-CENTERED VALUE ASSESSMENT- LESSONS FROM THE IVI OPEN-SOURCE VALUE PROJECT

    Oct 1, 2018, 00:00

  • PCN125 - FIRST INSIGHTS INTO COMPARING EXPENDITURES FOR TARGETED THERAPY AND SURVIVAL IN NSCLC

    Oct 1, 2018, 00:00

  • HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT

    Oct 1, 2018, 00:00

  • PRM260 - GENERATION OF RECONSTRUCTED INDIVIDUAL PATIENT DATA FROM DIGITIZED CURVES IN COST-EFFECTIVENESS MODEL- A DISCRETE OPTIMIZATION APPROACH

    Oct 1, 2018, 00:00

  • PMS34 - THE IMPACT OF DISEASE DURATION AND DISEASE ACTIVITY ON THE COST OF RHEUMATOID ARTHRITIS IN SPAIN- RESULTS FROM BURDEN OF RHEUMATOID ARTHRITIS ACROSS EUROPE A SOCIOECONOMIC SURVEY (BRASS)

    Oct 1, 2018, 00:00

  • PMU70 - PRESCRIPTION ANALYSIS OF HYPOCALORIC PERIPHERAL PARENTERAL NUTRITION AT A TERTIARY CARE HOSPITAL

    Oct 1, 2018, 00:00

  • PCV65 - EXPERT ANALYSIS ON COST ANALYSIS OF MANAGEMENT OF CARDIOVASCULAR DISEASE CO-MORBIDITIES

    Oct 1, 2018, 00:00

  • PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017

    Oct 1, 2018, 00:00

  • PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS- THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTS

    Oct 1, 2018, 00:00

  • PHP368 - THE FRENCH COMPASSIONATE USE OF MEDICINAL PRODUCTS PROGRAM (2012-2017)- HEALTH TECHNOLOGY ASSESSMENT AND PRICING IMPLICATIONS

    Oct 1, 2018, 00:00

  • PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PMH67 - COMPLIANCE WITH ANTIDEPRESSANT MEDICATION IN KOREA- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PDB134 - CHARACTERISTICS OF US ADULTS WITH CONTROLLED AND UNCONTROLLED TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PMU79 - THE USE OF NETWORK META-ANALYSIS TO COMPARE DIFFERENT MEASURES OF MEDICATION ADHERENCE

    Oct 1, 2018, 00:00

  • PUK17 - A COST-EFFECTIVENESS ANALYSIS OF RAASI – ENABLING PATIROMER FOR THE TREATMENT OF HYPERKALEMIA IN SWEDEN

    Oct 1, 2018, 00:00

  • PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINA

    Oct 1, 2018, 00:00

  • PCN243 - POST-LOE PRICING DYNAMICS IN ONCOLOGY- IMPACT OF MANDATORY PRICE DISCOUNTS ON LIST PRICES AND GENERIC UPTAKE

    Oct 1, 2018, 00:00

  • PCV59 - HEALTH INSURANCE COST OF ESSENTIAL (PRIMARY) HYPERTENSION IN HUNGARY- A NATIONWIDE, REAL-WORLD COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PMD17 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN BARBED AND CONVENTIONAL SUTURES AMONG PATIENTS UNDERGOING SPINE SURGERY

    Oct 1, 2018, 00:00

  • PHP228 - THE IMPACT OF LABEL EXTENSIONS ON THE REIMBURSED PRICE OF PHARMACEUTICAL PRODUCTS ASSESSED ACCORDING TO §35A SGB V IN GERMANY - ONCOLOGICAL AND METABOLIC DISEASES

    Oct 1, 2018, 00:00

  • PMD8 - COMPARATIVE ASSESSMENT OF MEASURING TECHNIQUES OF CHILDREN’S TEMPERATURE IN PEDIATRIC DEPARTMENT

    Oct 1, 2018, 00:00

  • PRM25 - INCORPORATING EXPERT OPINION TO IMPROVE ESTIMATES OF LONG-TERM SURVIVAL WHEN FOLLOW-UP OF EMPIRICAL STUDIES IS SHORT

    Oct 1, 2018, 00:00

  • PIH22 - ECONOMIC IMPACT OF DONOR HUMAN MILK VERSUS FORMULA FOR VERY LOW BIRTH WEIGHT INFANTS IN THE NEONATAL INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PRM105 - REAL WORLD EVIDENCE- DOES THE POPULARITY OF THE TERM REFLECT IN PUBLICATION NUMBERS?

    Oct 1, 2018, 00:00

  • PRM203 - LINGUISTIC VALIDATION OF THE CHRONIC KIDNEY DISEASE AND ANAEMIA QUESTIONNAIRE (CKDAQ), A PATIENT REPORT OUTCOMES ASSESSMENT (PRO), INTO 30 ASIA-PACIFIC LANGUAGES

    Oct 1, 2018, 00:00

  • PND124 - HUMANISTIC AND ECONOMIC BURDEN OF PROGRESSIVE SUPRANUCLEAR PALSY- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM173 - DISCRIMINATIVE VALIDITY OF THE EQ-5D-5L AND SF-12 IN OLDER ADULTS WITH ARTHRITIS

    Oct 1, 2018, 00:00

  • PMD151 - SURGICAL TREATMENT, COMPLICATIONS, HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH ACROMIOCLAVICULAR DISLOCATIONS

    Oct 1, 2018, 00:00

  • PCN346 - DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATES

    Oct 1, 2018, 00:00

  • PND12 - NATALIZUMAB VERSUS GLATIRAMER ACETATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PND68 - COST-EFFECTIVENESS OF TERIFLUNOMIDE COMPARED TO INTERFERON BETA-1B FOR RELAPSING MULTIPLE SCLEROSIS PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PND126 - SYSTEMATIC REVIEW OF THE BURDEN OF PEDIATRIC MULTIPLE SCLEROSIS IN NORTH AMERICA AND EUROPE

    Oct 1, 2018, 00:00

  • PGI19 - STANDARD-DOSE PROTON PUMP INHIBITOR IN THE INITIAL NON-ERADICATION TREATMENT OF DUODENAL ULCER- SYSTEMATIC REVIEW, NETWORK META-ANALYSIS, AND COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2018, 00:00

  • PCV148 - A SYSTEMATIC LITERATURE REVIEW ON HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL STROKE

    Oct 1, 2018, 00:00

  • PSY110 - PHARMACOECONOMICS OF DIFFERENT TREATMENTS FOR STEROID-REFRACTORY GRAFT VERSUS HOST REACTION- ANALYSIS OF TREATMENT RESULTS IN A SINGLE-CENTER STUDY

    Oct 1, 2018, 00:00

  • PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS

    Oct 1, 2018, 00:00

  • CE2 - COST-EFFECTIVENESS OF A NEW SINGLE INHALER TRIPLE THERAPY VERSUS A DUAL INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

    Oct 1, 2018, 00:00

  • PSY113 - ASSESSMENT OF BASIC HEALTH TECHNOLOGIES FOR ACROMEGALY PHARMACOTHERAPY IN UKRAINE

    Oct 1, 2018, 00:00

  • PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOW

    Oct 1, 2018, 00:00

  • PCV124 - HOSPITAL ADMISSIONS FOR HEART FAILURE IN ENGLAND; AN INCREASING BURDEN ON NHS RESOURCES AND THE FOCUS OF EFFECTIVE COST CONTAINMENT

    Oct 1, 2018, 00:00

  • PHP120 - WHAT DO WE STAND TO LOSE? THE PROPORTION OF US-OWNED PHARMACEUTICALS ON AUSTRALIA’S PHARMACEUTICAL BENEFITS SCHEME

    Oct 1, 2018, 00:00

  • PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLAND

    Oct 1, 2018, 00:00

  • PCV110 - TREATMENT WITH FREE TRIPLE COMBINATION THERAPY OF ATORVASTATIN, PERINDOPRIL, AMLODIPINE AND ATORVASTATIN IN PATIENTS WITH HYPERTENSION- A REAL-WORLD POPULATION STUDY IN ITALY.

    Oct 1, 2018, 00:00

  • PIN86 - COST SAVINGS TO BE EXPECTED FROM THE INTRODUCTION OF NEW ANTI-HIV GENERICS IN UNIVERSITY PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • CV4 - PATIENT AND CAREGIVER INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTS

    Oct 1, 2018, 00:00

  • PMH50 - TREATMENT OF OPIOID USE DISORDER IN ITALY- IS THERE SCOPE FOR POLICY CHANGE?

    Oct 1, 2018, 00:00

  • PMD132 - REAL-WORLD ECONOMIC AND CLINICAL OUTCOMES FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING RADIOFREQUENCY ABLATION USING THERMOCOOL® SF CATHETER VERSUS THERMOCOOL® CATHETER

    Oct 1, 2018, 00:00

  • PRM141 - COMPARISON OF NOVEL BAYESIAN METHODS USING EXTERNAL DATA TO IMPROVE SURVIVAL ESTIMATIONS FROM IMMATURE SURVIVAL DATA

    Oct 1, 2018, 00:00

  • PMD12 - AMBULATORY BLOOD PRESSURE MONITORING IN THE DIAGNOSIS AND MANAGEMENT OF ARTERIAL HYPERTENSION IN CURRENT MEDICAL PRACTICE IN ALGERIA- MAPA DZ STUDY - INTERIM ANALYSIS

    Oct 1, 2018, 00:00

  • PMS111 - PATIENTS’ PREFERENCES FOR TREATMENT OF PSORIATIC ARTHRITIS BASED ON A DISCRETE CHOICE EXPERIMENT. RESULTS OF THE COEPSO STUDY

    Oct 1, 2018, 00:00

  • PND38 - ECONOMIC IMPACT OF MULTIPLE SCLEROSIS IN PATIENTS WITH LOW PHYSICAL DISABILITY

    Oct 1, 2018, 00:00

  • PCP57 - LIQUID BIOPSIES IN EARLY DETECTION OF BREAST CANCER, METASTATIC PROGRESSION AND THERAPY OUTCOMES- OPPORTUNITIES AND CHALLENGES FOR THE PERSPECTIVE OF PATIENTS, PROVIDERS AND PAYERS

    Oct 1, 2018, 00:00

  • PRM269 - SYSTEMATIC LITERATURE REVIEW (SLR) EVALUATING QUALITY ASSESSMENT TOOLS (QAT)

    Oct 1, 2018, 00:00

  • PSS70 - ACNE AND ABSENTEEISM- RESULTS OF A REAL-LIFE STUDY

    Oct 1, 2018, 00:00

  • PRS55 - COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE

    Oct 1, 2018, 00:00

  • PCN318 - CONDUCTING AND REPORTING INDIRECT TREATMENT COMPARISONS- A CRITICAL APPRAISAL OF ONCOLOGY TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PCN242 - HOW FAR DOES HIGH EXPENDITURE IMPLY EFFECTIVENESS? A STUDY OF THE RELATION BETWEEN ONCOLOGICAL DRUG EXPENDITURE AND HEALTH OUTCOMES FROM 37 COUNTRIES

    Oct 1, 2018, 00:00

  • PRM182 - CULTURAL ADAPTATION AND LOCALISATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) INTO ARABIC VARIANTS TO ENSURE CULTURAL SUITABILITY.

    Oct 1, 2018, 00:00

  • PCN337 - HR+/HER2− ADVANCED BREAST CANCER TREATMENT, DISEASE PROGRESSION, AND SURVIVAL IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, AND MEXICO

    Oct 1, 2018, 00:00

  • PRM7 - THE USE OF NATURAL LANGUAGE PROCESSING TO ASSESS PATIENTS WITH BLEEDS IN THEIR NOTES IN THE OPTUM EHR DATABASE

    Oct 1, 2018, 00:00

  • PRM22 - SERVICE IMPACT MODELLING AS A TOOL TO SUPPORT MARKET ACCESS FOR HEALTH TECHNOLOGY INNOVATION

    Oct 1, 2018, 00:00

  • PMD164 - THE MANAGEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS (T2)- THE ROLE OF GLYCATED ALBUMIN

    Oct 1, 2018, 00:00

  • PMD186 - COMPARATIVE ASSESSMENT OF BODY TEMPERATURE MEASURING TECHNIQUES IN FEVERED CHILDREN AT PAEDIATRIC DEPARTMENT

    Oct 1, 2018, 00:00

  • PUK35 - WORK PRODUCTIVITY AND EQ-5D UTILITY OF PATIENTS WITH CHRONIC KIDNEY DISEASE BY ANEMIA SEVERITY- POOLED RESULTS FROM THREE CROSS-SECTIONAL INTERNATIONAL SURVEYS

    Oct 1, 2018, 00:00

  • PMS1 - COMPARATIVE EFFECTIVENESS OF BARICITINIB VERSUS SARILUMAB IN RHEUMATOID ARTHRITIS- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PRM222 - STUDY OF THE SEVERITY OF VASO-OCCLUSIVE CRISIS FOR PATIENT SUFFERING FROM SICKLE CELL DISEASE IN FRANCE USING A MACHINE LEARNING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINA

    Oct 1, 2018, 00:00

  • PRS7 - PROPHYLACTIC VERSUS SELECTIVE USE OF SURFACTANT IN PRETERM INFANTS IN KOREA - KOREAN NEONATAL NETWORK

    Oct 1, 2018, 00:00

  • PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PMD165 - EVALUATING DIGITAL HEALTH TECHNOLOGIES- A REVIEW OF HTA GUIDANCE AND ASSESSMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PMU17 - RETROSPECTIVE STUDY OF PATIENTS USING ELBASVIR/GRAZOPREVIR IN FRANCE

    Oct 1, 2018, 00:00

  • PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGAL

    Oct 1, 2018, 00:00

  • PMS108 - HIGH-FREQUENCY ULTRASOUND EXAMINATION OF LATERAL ANKLE LIGAMENT INJURIES IN CHILDREN

    Oct 1, 2018, 00:00

  • PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES.

    Oct 1, 2018, 00:00

  • PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PHP244 - BRIDGING THE GAP- ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMD3 - METHODS FOR QUANTIFYING POSTERIOR CAPSULAR OPACIFICATION AND THE IMPACT OF INTRAOCULAR LENS MATERIAL ON SEVERITY SCORES - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRS71 - WASTEFUL HEALTHCARE SPENDING ON MEDICATION OVERSUPPLY IN ROUTINE USES OF COMBINED INHALED CORTICOSTEROID AND LONG-ACTING BETA2-AGONISTS (ICS/LABA) INHALERS

    Oct 1, 2018, 00:00

  • PRM99 - TRENDS IN OPIOID PRESCRIBING IN PRIMARY CARE PHYSICIAN OFFICES IN THE UNITED STATES- 2006-2015

    Oct 1, 2018, 00:00

  • PSY76 - ECONOMIC BURDEN OF DISEASES RELATED TO OVERWEIGHT AND OBESITY IN COLOMBIA

    Oct 1, 2018, 00:00

  • PSY197 - LIMITATIONS OF THE EQ5D INSTRUMENT IN THE ASSESSMENT OF QUALITY OF LIFE IN CHRONIC RARE DISEASES – A CASE STUDY FROM FCS

    Oct 1, 2018, 00:00

  • PCN292 - CANCER DRUGS IN GERMANY- HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASE

    Oct 1, 2018, 00:00

  • PHP284 - TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PDB21 - COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS IN TYPE II DIABETES DERIVED FROM AN OVERVIEW OF 55 SYSTEMATIC REVIEWS

    Oct 1, 2018, 00:00

  • PUK22 - ESTIMATES OF KIDNEY STONES COSTS. AN ANALYSIS OF CLINICAL AND ADMINISTRATIVE DATA TO MEASURE THE BURDEN OF KIDNEY STONES IN ITALY

    Oct 1, 2018, 00:00

  • PRS77 - SOCIOECONOMIC DETERMINANTS OF SMOKING IN GREECE

    Oct 1, 2018, 00:00

  • PCV161 - FOCUS ON LIFE QUALITY IN RECONSTRUCTION VASCULAR SURGERY

    Oct 1, 2018, 00:00

  • PIN108 - HUMAN PAPILLOMAVIRUS VACCINATION UPTAKE BARRIERS AMONG ADOLESCENTS AND THEIR PARENTS IN THE RUSSIAN FEDERATION

    Oct 1, 2018, 00:00

  • PMS120 - THE IMPACT OF RHEUMATOID ARTHRITIS (RA) ON A PATIENT’S ABILITY TO WORK AND EARLY RETIREMENT DUE TO RA

    Oct 1, 2018, 00:00

  • PCN317 - THE CANCER DRUGS FUND- KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SET

    Oct 1, 2018, 00:00

  • PCP53 - A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATION

    Oct 1, 2018, 00:00

  • PIH44 - OLDER PEOPLE WITH LONG TERM CONDITIONS USING TECHNOLOGIES SUPPORTING HOME BASED CARE- PATTERNS OF RESOURCE USE, COSTS AND HEALTH RELATED QUALITY OF LIFE

    Oct 1, 2018, 00:00

  • PRM237 - PERFORMANCE OF PROPENSITY SCORE MATCHING IN SMALL SAMPLES - SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PHP164 - PHARMACEUTICAL POLICIES IN PORTUGAL – TRENDS AND IMPACT

    Oct 1, 2018, 00:00

  • PND150 - IMPACT OF INOTERSEN ON CONDITION-SPECIFIC QUALITY OF LIFE (QOL) FOR PATIENTS WITH HATTR AMYLOIDOSIS- RESULTS FROM A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

    Oct 1, 2018, 00:00

  • PMH34 - A CONCEPTUAL ECONOMIC MODEL FOR DIGITAL INTERVENTIONS IN SERIOUS MENTAL ILLNESS

    Oct 1, 2018, 00:00

  • PCN46 - DURABLE THERAPY IN FRONTLINE CLL IMPROVES OS

    Oct 1, 2018, 00:00

  • PSY140 - DEXMEDETOMIDINE UTILISATION STUDY IN THE INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • PHP27 - EFFECTIVENESS OF COMMUNITY-BASED INTERVENTIONS FOR THE PREVENTION AND TREATMENT OF MENTAL HEALTH PROBLEMS AND MENTAL DISORDERS IN THE GENERAL POPULATION- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMH59 - IDENTIFYING THE ASSOCIATION BETWEEN OUTCOMES AND QUALITY OF LIFE (QOL) OR HEALTH CARE RESOURCE UTILISATION (HCRU) IN SCHIZOPHRENIA- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PUK37 - USE OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) INSTRUMENTS IN CLINICAL TRIALS OF ANAEMIA OF CHRONIC KIDNEY DISEASE (CKD)

    Oct 1, 2018, 00:00

  • PRM123 - AN OVERVIEW OF OPEN-SOURCE MODELS IN HEALTH ECONOMICS

    Oct 1, 2018, 00:00

  • PMD86 - POTENTIAL COST-EFFECTIVENESS OF SPECTRAL PHOTON-COUNTING COMPUTED TOMOGRAPHY (SPCCT) VERSUS CT COMBINED TO CT ANGIOGRAPHY (CTA) IN THE IDENTIFICATION AND TREATMENT OF ISCHAEMIC STROKE PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PMU88 - HEALTH EXPECTANCIES FROM CLINICAL DATA- AN ALTERNATIVE TO THE SULLIVAN METHOD?

    Oct 1, 2018, 00:00

  • PCV46 - PHARMACOECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS OF IVABRADINE IN CHINA

    Oct 1, 2018, 00:00

  • PCN202 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PDB98 - TYPE 2 DIABETES- REAL-LIFE STUDY BASED ON SNIIRAM DATA OF PATIENTS INITIATING AGLP1 IN 2016

    Oct 1, 2018, 00:00

  • PCN164 - THE APPLICATION OF A RESPONSE-BASED MODELLING APPROACH WITH A LANDMARK POINT- IMPLICATIONS AND CHALLENGES FOR THE ECONOMIC EVALUATION OF NIVOLUMAB FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PMD76 - WHICH INTENSIVE CARE ANALYTICS ARE A WORTHWHILE INVESTMENT FOR DEVELOPERS? AN EARLY HEALTH TECHNOLOGY ASSESSMENT.

    Oct 1, 2018, 00:00

  • PSY28 - EPIDEMIOLOGY OF RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIES

    Oct 1, 2018, 00:00

  • PCN231 - PRICING, AVAILABILITY, AFFORDABILITY, PRICE COMPONENTS OF ESSENTIAL ANTICANCER MEDICINES IN ADDIS ABABA, ETHIOPIA

    Oct 1, 2018, 00:00

  • PMD97 - TECHNOLOGICAL-ECONOMIC COMPARISON OF ENDODONTICS TECHNIQUE WITH FOCUS ON NIKL-TITAN SYSTEMS

    Oct 1, 2018, 00:00

  • PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRS23 - PERSISTENCE TO COPD THERAPIES AND IMPACT ON COSTS RELATED TO HEALTHCARE CONSUMPTION- A FRENCH CLAIMS DATA STUDY

    Oct 1, 2018, 00:00

  • PMD111 - THE COST-EFFECTIVENESS OF BIMODAL AIDING COMPARED TO UNILATERAL AND BILATERAL COCHLEAR IMPLANT USE IN ADULTS WITH BILATERAL SEVERE TO PROFOUND DEAFNESS

    Oct 1, 2018, 00:00

  • PMD102 - COST-EFFECTIVENESS OF USING [18F]FLUTEMETAMOL IN THE CLINICAL EVALUATION OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR SUSPECTED DEMENTIA IN SPAIN

    Oct 1, 2018, 00:00

  • CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES- EXPLORING A NEW APPLICATION OF THE EQ VAS

    Oct 1, 2018, 00:00

  • PSY111 - PHARMACOECONOMIC EVALUATION OF BIOSIMILAR RECOMBINANT ALPHA-EPOETIN IN THE TREATMENT OF ANEMIA IN HEMODIALYSIS PATIENTS

    Oct 1, 2018, 00:00

  • PRM253 - EXPLORATION OF NETOWRK META-REGRESSION MODELS APPLIED TO COMPLEX EVIDENCE NETWORKS

    Oct 1, 2018, 00:00

  • PRS31 - THE ECONOMIC IMPACT OF OPTIMIZED POST-HOSPITALIZATION MANAGEMENT FOR AN EXACERBATION IN COPD PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

    Oct 1, 2018, 00:00

  • PDB28 - TYPE 2 DIABETES- CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT- A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Oct 1, 2018, 00:00

  • PRM198 - STANDARD ERROR OF MEASUREMENT AND SMALLEST DETECTABLE CHANGE OF THE SARQOL® QUESTIONNAIRE- AN ANALYSIS OF SUBJECTS FROM 8 VALIDATION STUDIES

    Oct 1, 2018, 00:00

  • PMD45 - BIOMARKER-GUIDED RISK ASSESSMENT OF ACUTE KIDNEY INJURY- RESULTS OF A COSTING MODEL FROM A UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PMD95 - ECONOMIC EVALUATION OF STRATEGIES WITH/WITHOUT P16 FOR OPPORTUNISTIC CERVICAL CANCER SCREENING

    Oct 1, 2018, 00:00

  • PIN113 - ASSESSMENT OF THE EFFICACY AND SAFETY OF ANIDULAFUNGIN, COMPARED WITH OTHER AVAILABLE ANTIFUNGALTHERAPIES TO TREAT INVASIVE CANDIDIASIS- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REAL

    Oct 1, 2018, 00:00

  • PSY208 - PATIENTS’ PREFERENCES FOR PSORIASIS TREATMENT BASED ON A DISCRETE CHOICE EXPERIMENT. COEPSO STUDY

    Oct 1, 2018, 00:00

  • PMD161 - CLINICAL IMPACT OF A PHARMACEUTICAL PROFESIONAL SERVICE INTERVENTION WITH OR WITHOUT A MULTI-COMPARTMENT MEDICATION IN NON-ADHERENT, UNCONTROLLED, CHRONIC HYPERTENSIVE, POLYMEDICATED PATIENTS IN SPANISH COMMUNITY PHARMACIES. SEFAC- ...

    Oct 1, 2018, 00:00

  • PSY2 - IDENTIFICATION OF POTENTIAL BIAS FROM DATA SOURCES AND STUDY DESIGNS USED TO ESTIMATE PLATELET TRANSFUSION ADVERSE EVENT RATES

    Oct 1, 2018, 00:00

  • PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015

    Oct 1, 2018, 00:00

  • PMU111 - BEST PRACTICE METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, EVALUATION, AND IMPLEMENTATION OF INTERVIEWER-ADMINISTERED PATIENT-REPORTED OUTCOMES (ADPROS)

    Oct 1, 2018, 00:00

  • PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PIH32 - INNOVATIVE PAYMENT MECHANISM- SOLVING INEQUITIES FOR HER2 (-) BREAST CANCER CASES IN CHILE.

    Oct 1, 2018, 00:00

  • PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5

    Oct 1, 2018, 00:00

  • PMD128 - ECONOMIC AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE- A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT

    Oct 1, 2018, 00:00

  • PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP224 - TEMPORARY ACCESS STRUCTURES FOR INNOVATIVE, HIGH-VALUE THERAPIES- COMPARISON OF MODELS AND CONSEQUENT REIMBURSEMENT TIMELINES

    Oct 1, 2018, 00:00

  • PMD138 - IMPACTS OF NEW EU MDRIVDR REGULATIONS FOR TURKEY

    Oct 1, 2018, 00:00

  • PCV41 - COST IMPACT ANALYSIS OF USING IMPROVE® TOOL FOR VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PIN54 - COST-EFFECTIVENESS OF INTRODUCING MEN VACCINATION AGAINST HUMAN PAPILLOMAVIRUS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMD44 - COST COMPARISON OF RECHARGEABLE AND NON-RECHARGEABLE DEEP BRAIN STIMULATION DEVICES IN THE NORDIC COUNTRIES

    Oct 1, 2018, 00:00

  • PCN357 - SATISFACTION WITH HEALTH CARE IN LOCALLY ADVANCED HEAD AND NECK CANCER MEXICAN PATIENTS TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PRM167 - MAPPING THE SF-36 TO EQ-5D-3L IN RANDOMIZED TRIAL- THE EMOCAR STUDY (MAY 2011 – APRIL 2016)

    Oct 1, 2018, 00:00

  • PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L- COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE

    Oct 1, 2018, 00:00

  • PRS57 - ECONOMIC EVALUATION OF SINGLE INHALER TRIPLE THERAPY FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING THE GALAXY MODEL

    Oct 1, 2018, 00:00

  • PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIA

    Oct 1, 2018, 00:00

  • PCN380 - THE PROGNOSTIC SIGNIFICANCE OF HEALTH-RELATED QUALITY OF LIFE FROM CANCER RANDOMIZED CONTROLLED TRIALS- A SYSTEMATIC EVALUATION OF THE STATISTICAL METHODS

    Oct 1, 2018, 00:00

  • PUK11 - ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE RELATED COMPLICATIONS AND THERAPIES IN CHINA- QUANTIFYING THE COSTS OF CARDIOVASCULAR EVENTS, BLOOD TRANSFUSION FOR ANEMIA AND DIALYSIS

    Oct 1, 2018, 00:00

  • PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA- A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND48 - HEALTH AND ECONOMIC BURDEN OF PARKINSON’S DISEASE IN FINLAND

    Oct 1, 2018, 00:00

  • PGI12 - PREDICTORS OF READMISSION FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION USING THE FRENCH HEALTH INSURANCE DATABASE

    Oct 1, 2018, 00:00

  • PRM137 - MODELING THE DISTRIBUTION OF TBEV-INFECTED TICKS IN GERMANY TO ESTIMATE TBE-INFECTIONS IN HUMANS

    Oct 1, 2018, 00:00

  • PIN101 - ACUTE GASTROENTERITIS HOSPITALIZATIONS- EXPLORING SPATIO-TEMPORAL PATTERNS AND SELF-FINANCED ROTAVIRUS VACCINATION EFFECT

    Oct 1, 2018, 00:00

  • PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PHP283 - PHARMACEUTICAL CARE IN RESIDENTIAL SOCIO-HEALTH CENTERS- OPTIMISATION OF STORAGE AND DISPENSING CIRCUIT

    Oct 1, 2018, 00:00

  • PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCV30 - REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PMU69 - DESCRIPTION OF HEALTH CARE ACTIVITY OF A NUTRITION AREA MANAGED BY A HOSPITAL PHARMACY SERVICE

    Oct 1, 2018, 00:00

  • PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN ...

    Oct 1, 2018, 00:00

  • PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)

    Oct 1, 2018, 00:00

  • PMH62 - DEPRESCRIBING OF BENZODIAZEPINES AMONGST THE PATIENTS OF DEPARTMENT OF PSYCHIATRY IN A TERTIARY CARE HOSPITAL, BANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PDB9 - ASSOCIATION BETWEEN CLASS OF ANTIDIABETIC DRUGS AND INCIDENCE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELITUS- A PROPORTIONAL HAZARD ANALYSIS USING DEEP LEARNING FOR RISK ADJUSTMENT

    Oct 1, 2018, 00:00

  • PSY72 - COST OF ILLNESS ANALYSIS- ECONOMIC BURDEN IN DIRECT COSTS OF OBESITY-RELATED CO-MORBIDITIES – STROKE, MYOCARDIAL INFARCTION, TYPE 2 DIABETES - IN RUSSIA

    Oct 1, 2018, 00:00

  • PDB124 - PERSONALIZED DIABETES MANAGEMENT- WHAT DO PATIENTS WITH DIABETES MELLITUS PREFER?

    Oct 1, 2018, 00:00

  • PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY- A LANDSCAPE ANALYSIS

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56 (current)
  • 57
  • 58
  • 59
  • 60
  • »